Login to Your Account

EPO Warning Nicks Amgen; Off-Label Risks Told Earlier

By Aaron Lorenzo and Randall Osborne

Monday, March 12, 2007
Amgen Inc. headed off worse damage from Friday's news of the "black box" label warning for the firm's flagship red-blood cell boosters Aranesp and Epogen by pointing out that problems arise mainly in cases where the drugs are given at levels beyond those approved, and such cases rarely occur. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription